Maxim Group Keeps a Buy Rating on CASI Pharmaceuticals

By Ryan Adsit

In a report released today, Gabrielle Zhou from Maxim Group reiterated a Buy rating on CASI Pharmaceuticals (NASDAQ: CASI), with a price target of $4. The company’s shares opened today at $0.99.

Zhou noted:

“CASI announced that the company will present P2 data for ENMD-2076 in an abstract titled “‘Phase II Clinical and Molecular Trial of Oral ENMD-2076 in Clear Cell Ovarian Cancer (CCOC)” at ASCO (American Society of Clinical Oncology, June 2-6, 2017) demonstrating improved progression-free survival (PFS).”

According to, Zhou is ranked 0 out of 5 stars with an average return of -13.0% and a 22.0% success rate. Zhou covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, ContraVir Pharmaceuticals Inc, and Sciclone Pharmaceuticals.

CASI Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $4.

The company has a one year high of $1.76 and a one year low of $0.82. Currently, CASI Pharmaceuticals has an average volume of 42.89K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs with commercial focus on the China market. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. The drugs are Captisol-Enabled, ZEVALIN and MARQIBO. CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.